Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Head and Neck Neoplasms 2Stomach Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Composite Lymphoma 1Colorectal Neoplasms 1

Interventions

Rituximab 13Cyclophosphamide 10Lenalidomide 8venetoclax 5ibrutinib 5fludarabine 4CT-P10 4orelabrutinib 3obinutuzumab 3fludarabine phosphate 3Vincristine 3tafasitamab 2pirtobrutinib 2copanlisib 2acalabrutinib 2Whole-Body Irradiation 2Tacrolimus 2Specimen Handling 2Prednisone 2Nivolumab 2Mycophenolic Acid 2Melphalan 2Magnetic Resonance Spectroscopy 2Hyaluronoglucosaminidase 2Etoposide 2Doxorubicin 2Busulfan 2Bendamustine Hydrochloride 2selinexor 1prednylidene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, B-Cell, Marginal Zone × ALX148 × Clear all
NCT05025800 2026-03-20

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Composite Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡